The COMP006 study has completed its active delivery phase after the final participant attended the concluding visit at Oxford’s NIHR Clinical Research Facility, operated by Oxford Health.
The research forms part of Compass Pathways’ international Phase 3 programme assessing COMP360 psilocybin therapy for depression that has not responded to treatment.
Dr Katharine Smith, a consultant psychiatrist with Oxford Health NHS Foundation Trust, is COMP006’s principal investigator at Oxford.
She described the final participant visit as an important milestone for the research and expressed appreciation to those who contributed their time and commitment, together with the study team that supported them throughout.
Further analysis remains under way, but the completion of this stage is expected to improve understanding of how the investigational therapy could help people experiencing treatment-resistant depression.
Oxford-based recruitment and delivery began in 2024, with participants attending treatment sessions, follow-up assessments and long-term monitoring.
Earlier in the year, Compass Pathways published interim findings showing a statistically significant decrease in depressive symptoms six weeks after two 25mg doses of COMP360 when compared with the group receiving 1mg.
The company also confirmed that regulatory discussions with the US Food and Drug Administration are continuing as part of its submission process.
Meanwhile, the Oxford Health CRF team intends to investigate additional psychedelic therapies and other potential treatments for a range of mental health conditions.